GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover
Deal values cancer drug developer Nuvalent at $124 per shareThat is a 40% premium to the US-listed firm’s…
UK equities slip as Middle East impasse drives oil higher
June 3 (Reuters) – UK shares declined on Wednesday as hostilities in the Middle East flared up again,…